[The effectivity of carminomycin in combination with dibromodulcitol on human tumor cells in vitro (author's transl)].
In parallel to the clinical study CMEA 0102 and an experimental study with animal models the effectivity of carminomycin (CRM) in combination with dibromodulcitol (DBD) was tested on human mesothelioma cells in vitro. The cytostatic effect was evaluated by means of 3H-thymidine incorporation into DNA compared to controls. The used mesothelioma cells are more sensitive to CRM than to DBD in relation to their effective drug concentrations. 1.2 x 10(18) mol/l CRM inhibited 3H-thymidine incorporation to 30.6% +/- 9.3 and 3.9 x 10(-6) mol/l DBD to 35.3% +/- 18.3%. In 14/27 experiments the combination of CRM plus DBD in these low concentrations increased effectivity more than the summarized inhibition value, caused by single applied agents in vitro. However, the statistical evaluation of all results didn't confirm these observations. Alternating addition of the second antineoplastic agent three hours after the first did not result in additional effectivity compared to simultaneous one.
D002360:Carubicin / Q000627:therapeutic use*; D002478:Cells, Cultured; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy*; D008936:Mitolactol / Q000627:therapeutic use*; D013936:Thymidine / Q000378:metabolism
D002360:Carubicin; D008936:Mitolactol; D013936:Thymidine; D003630:Daunorubicin
Die Wirksamkeit von Carminomycin in Kombination mit Dibromodulcitol auf Tumorzellen des Menschen in vitro.